Changeflow GovPing Pharma & Drug Safety CRISPR/Cas9 Gene Editing Method for Beta-Amyloi...
Routine Notice Added Final

CRISPR/Cas9 Gene Editing Method for Beta-Amyloid Pathway Attenuation

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

USPTO published patent application US20260097136A1 filed by Wisconsin Alumni Research Foundation on November 12, 2025. The application covers CRISPR/Cas9 constructs designed for C-terminal truncation of human amyloid precursor protein (APP) to attenuate the beta-amyloid pathway implicated in Alzheimer's disease, along with methods of making and using such constructs.

The publication provides public notice of the claimed gene-editing technology and its potential therapeutic applications in neurodegenerative disease. No enforceable rights are granted until a patent issues following examination.

What changed

USPTO published patent application US20260097136A1, a new biotech patent application from Wisconsin Alumni Research Foundation covering CRISPR/Cas9 constructs for C-terminal truncation of human amyloid precursor protein (APP) and methods of making and using the constructs.

Affected parties including biotech researchers, pharmaceutical companies, and gene therapy developers should monitor this application as it progresses through examination. If the patent issues, it could cover CRISPR-based therapeutic approaches targeting APP for Alzheimer's disease treatment, potentially limiting freedom to operate in this space without a license.

What to do next

  1. Monitor for patent issuance and examiner actions
  2. Review claims for potential infringement implications

Archived snapshot

Apr 12, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

GENE EDITING-BASED METHOD OF ATTENUATING THE BETA-AMYLOID PATHWAY

Application US20260097136A1 Kind: A1 Apr 09, 2026

Assignee

Wisconsin Alumni Research Foundation

Inventors

Subhojit Roy, Jichao Sun

Abstract

Described herein are CRISPR/Cas9 constructs designed for the C-terminal truncation of human amyloid precursor protein (APP) as well as methods of making and using such a construct.

CPC Classifications

A61K 48/0066 A61K 9/0019 A61K 48/0008 A61K 48/0058 A61K 48/0075 A61P 25/28 C07K 14/4711 C12N 9/22 C12N 15/102 C12N 15/907 C12N 2310/20 C12N 2740/16043 C12N 2750/14143

Filing Date

2025-11-12

Application No.

19387161

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 9th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260097136A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254.1 Biotechnology
Activity scope
Gene therapy development Biotechnology R&D
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!